Hypoglycemia in the setting of advanced gastrointestinal stromal tumor

American Surgeon

Volumn 72, Issue 12, 2006, Pages 1225-1230

  Guiteau, Jacfranz ^a   Fanucchi, Michael ^a   Folpe, Andrew ^a   Staley III, Charles A ^a   Kooby, David A ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; C PEPTIDE; FLUORODEOXYGLUCOSE F 18; GLUCAGON; GLUCOSE; IMATINIB; INSULIN; PROINSULIN; SOMATOMEDIN; STEM CELL FACTOR RECEPTOR; TETRACOSACTIDE; THYROTROPIN; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ABDOMINAL MASS; ABDOMINAL SWELLING; ADVANCED CANCER; AGED; ARTICLE; CANCER SURGERY; CASE REPORT; CONSTIPATION; DEHYDRATION; DETERIORATION; DIAGNOSTIC IMAGING; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GLUCOSE BLOOD LEVEL; HEALTH STATUS; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LEIOMYOSARCOMA; LETHARGY; MENTAL HEALTH; NAUSEA; PERITONEUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; SPINDLE CELL CARCINOMA; STOMACH; TUMOR BIOPSY; TUMOR RECURRENCE; VOMITING; ABDOMINAL TUMOR; BLOOD; DIFFERENTIAL DIAGNOSIS; DRUG ANTAGONISM; PALLIATIVE THERAPY; PARANEOPLASTIC SYNDROME;

ABDOMINAL NEOPLASMS; AGED; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; HYPOGLYCEMIA; LEIOMYOSARCOMA; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; PARANEOPLASTIC SYNDROMES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 33846939042     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Feliciano D. Image of the month. Arch Surg 2001;136: 597-9.
2. van de Rijn M, Hendrickson MR, Rouse RV. CD34 expression by gastrointestinal tract stromal tumors. Hum Pathol 2004; 25:766-71.
3. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
4. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259-69.
5. Davila R, Faigel D. GI stromal tumors. Gastrointest Endosc 2003;58:80-8.
6. Clary B, DeMatteo R, Lewis J, et al. Gastrointestinal stromal tumors and leiomyosarcoma of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol 2001;8:290-9.
7. Heinrich M, Rubin B, Longley B, Fletcher J. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002;33:484-95.
8. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005;23:5357-64.
9. Singer S, Rubin B, Lux M, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002;20:3898-905.
10. Antonescu C, Sommer G, Sarran L, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003;9:3329-37.
11. Miettinen M, El-Rifai W, Sobin L, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002;33:478-83.
12. Fletcher C, Berman J, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-65.
13. Tornoczky T, Kover E, Pajor L. Frequent occurrence of low grade cases among metastatic gastrointestinal stromal tumours. J Clin Pathol 2003;56:363-7.
14. Eisenberg B, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004;11:465-75.
15. Dematteo R, Heinrich M, El-Rifai W, Demetri G. Clinical management of gastrointestinal tumors: before and after STI-571. Hum Pathol 2002;33:466-77.
16. Dematteo R. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol 2002;9:831-9.
17. Hughes TP, Kaeda J, Branford S, et al. International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon-α plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32.
18. Demetri G. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib: mechanisms, successes, and challenges to rational drug development. Hematol Oncol Clin North Am 2002;16:472-80.
19. Demetri G, Von Mehren M, Blanke C, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
20. Agarwala S. Cancer screening and diagnosis: paraneoplastic syndromes. Med Clin N Am 1996;80:173-84.
21. Beckers M, Slee P, Van Doom J. Hypoglycemia in a patient with a gastrointestinal stromal tumour. Clin Endocrinol (Oxford) 2003;59:402-6.
22. Camci C, Paydas S, Sahin B, Cosar E. Malignant lymphoma with severe hypoglycemia. Eur J Cancer 1996;32A:2185.
23. Kruskel JB, Kane RA. Paraneoplastic hypoglycemia associated with a hepatic hemangiopericytoma. J Ultrasound Med 2002;21:927-32.
24. Ford-Dunn S, Smith A. Tumour-induced hypoglycaemia. Palliat Med 2002;16:357-8.